Vaishali Pharma Limited

Equities

VAISHALI

INE972X01014

Pharmaceuticals

Market Closed - NSE India S.E. 07:40:31 2024-07-05 EDT 5-day change 1st Jan Change
161.6 INR -4.15% Intraday chart for Vaishali Pharma Limited +3.07% -11.19%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Vaishali Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
Vaishali Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Vaishali Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Vaishali Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Vaishali Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
Vaishali Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Vaishali Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Vaishali Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
Vaishali Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2022 CI
Vaishali Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021 CI
Vaishali Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021 CI
Vaishali Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2021 CI
Vaishali Pharma Limited Receives Supply Orders in Excess of USD 100,000 from Russia CI
Vaishali Pharma Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021 CI
Vaishali Pharma Limited Receives an Order Worth USD 270,000 CI
Vaishali Pharma Limited Initiates 30 Products Registration in Central African Countries CI
Vaishali Pharma Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020 CI
Vaishali Pharma Limited Receives Another Bulk Order Worth INR 320 Million of PPE KITS CI
Vaishali Pharma Limited Enters into In-Licensing Agreement for the U.S.A Market CI
Vaishali Pharma Limited Provides Updates on the Major Bulk Order of INR 160 Million for PPE Kits & Covid -19 Medical Kits CI
Vaishali Pharma : Secures over $2 Million Bulk Order for PPEs and COVID-19 Related Products; Shares Soar 10% MT
Vaishali Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2020 CI
1,325,000 Equity Shares of Vaishali Pharma Limited are subject to a Lock-Up Agreement Ending on 31-AUG-2020. CI
Vaishali Pharma Limited Reports Earnings Results for the Full Year Ended March 31, 2020 CI
Vaishali Pharma Launches Vipravita C ­(Immunity Booster Vitamin C Supplements) CI
Chart Vaishali Pharma Limited
More charts
Vaishali Pharma Limited is an India-based pharmaceutical company. The Company is engaged in dealing in pharmaceutical ingredient, pharmaceutical formulations, surgical products, herbal and nutraceutical products, veterinary supplements operating in domestic and export market. Its product categories include active pharmaceutical ingredients (APIs), formulation brands, formulations, herbal, nutraceuticals, oncology, surgical and veterinary, among others. It offers APIs, including antibiotics, anti-ulcer, anti-inflammatory/analgesic/anti-pyretic, anti-malarial, cardiac, anti-diabetic, anti-cold/anti-allergic, anti-diarrheal/anti-protozoal/anti-parasitic, anti-viral, anti-epileptic, anti-asthmatic, anti-fungal, anti-platelet agent, skeletal muscle relaxant, and anti-helmintic drugs, as well as excipients, topical steroids, corticosteroids, and enzymes. The Company markets approximately 1,500 products and has more than 200 brands, around 35 countries.
More about the company
  1. Stock Market
  2. Equities
  3. VAISHALI Stock
  4. News Vaishali Pharma Limited
  5. Vaishali Pharma : Secures over $2 Million Bulk Order for PPEs and COVID-19 Related Products; Shares Soar 10%